Terms: = Lymphoma AND HSP90AA1, ENSG00000080824, 3320, P07900, LAP2, HSPN, HSPCAL4, HSPCAL1, HSPCA, HSPC1, HSP90N, HSP90A, Hsp90, Hsp89, HSP86, FLJ31884 AND Clinical Outcome
3 results:
1. Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance.
Chen Z; Akbay E; Mikse O; Tupper T; Cheng K; Wang Y; Tan X; Altabef A; Woo SA; Chen L; Reibel JB; Janne PA; Sharpless NE; Engelman JA; Shapiro GI; Kung AL; Wong KK
Clin Cancer Res; 2014 Mar; 20(5):1204-1211. PubMed ID: 24327273
[TBL] [Abstract] [Full Text] [Related]
2. Correlation of seven biological factors (hsp90a, p53, MDM2, Bcl-2, Bax, Cytochrome C, and Cleaved caspase3) with clinical outcomes of ALK+ anaplastic large-cell lymphoma.
Li HL; Huang XP; Zhou XH; Ji TH; Wu ZQ; Wang ZQ; Jiang HY; Liu FR; Zhao T
Biomed Environ Sci; 2011 Dec; 24(6):630-41. PubMed ID: 22365399
[TBL] [Abstract] [Full Text] [Related]
3. Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death.
Zappasodi R; Pupa SM; Ghedini GC; Bongarzone I; Magni M; Cabras AD; Colombo MP; Carlo-Stella C; Gianni AM; Di Nicola M
Cancer Res; 2010 Nov; 70(22):9062-72. PubMed ID: 20884630
[TBL] [Abstract] [Full Text] [Related]
